ENTA Share Price Performance
US$10.33
-1.22 (-10.56%)
Price US$10.33
Share PriceUS$10.33
Enanta Pharmaceuticals, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
ENTA Community Narratives
There are no narratives available yet.
Enanta Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 17, 2025
- Earnings per share (EPS)
- -4.30
- Gross Margin
- 100.00%
- Net Profit Margin
- -141.98%
- Debt/Equity Ratio
- 188.0%
Enanta Pharmaceuticals, Inc. Competitors
Snowflake Analysis
About ENTA
- Founded
- 1995
- Employees
- 131
- CEO
- WebsiteView website
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 1.2%
- 3 Months: 8.5%
- 1 Year: 17.7%
- Year to Date: 14.8%
The market is up 1.2% over the last week, with the Information Technology sector leading the way, up 2.4%. The market is up 18% over the last 12 months. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›